Taiho Pharmaceutical Company

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

StapleBio is a biotechnology company dedicated to the research and development of pharmaceuticals utilizing staple nucleic acid technology. The company has created a next-generation platform that hybridizes selectively with target messenger ribonucleic acid (mRNA) to induce a higher-order RNA structure known as RNA G-quadruplex (RGq). This innovative approach allows for the modulation of target protein expression levels without relying on enzymatic processes, distinguishing it from traditional RNA interference and antisense technologies. By enabling the introduction of artificial nucleic acids across various sequences, StapleBio’s technology aims to facilitate advancements in the detection and treatment of conditions such as cancer, central nervous system disorders, autoimmune diseases, and viral infections.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

AuB, Inc. is a company based in Chuo, Japan, founded in 2015, that specializes in the research and development of supplements, food, and beverages aimed at enhancing the intestinal environment of athletes. The company focuses on analyzing intestinal microflora to support improved athletic performance and overall health. AuB develops health supplements and cosmetics derived from microbiome studies and stool sample analyses, and offers dietary improvement services tailored to the specific needs of athletes based on their intestinal flora data. Through these innovative products and services, AuB aims to promote better nutrition and health, ultimately contributing to enhanced athletic performance.

Quentis Therapeutics, Inc. is a biotechnology company based in New York, founded in 2016. The company specializes in developing immunotherapies that target endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By addressing ER stress, Quentis aims to enhance the immune system's capacity to combat cancer, providing patients with innovative treatment options. Its therapeutic approach focuses on awakening anti-tumor immunity, thereby potentially improving outcomes for individuals facing various forms of cancer.